12:00 AM
 | 
Jun 11, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Insulin Degludec regulatory update

Novo said FDA extended the PDUFA date by 3 months for an NDA for insulin Degludec to treat Type I and...

Read the full 83 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >